Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III bapineuzumab could be shaky and same-stage dimebon possibly more solid, but victory with either could spell ‘blockbuster.’
You may also be interested in...
Antitrust Enforcement Under Obama: Pfizer-Wyeth Offers An Early Test
President Obama pledged to reinvigorate antitrust enforcement during his campaign for the Oval Office. Pfizer's proposed acquisition of Wyeth gives the administration an early opportunity to test that promise
Antitrust Enforcement Under Obama: Pfizer-Wyeth Offers An Early Test
President Obama pledged to reinvigorate antitrust enforcement during his campaign for the Oval Office. Pfizer's proposed acquisition of Wyeth gives the administration an early opportunity to test that promise
Pfizer Backs Out Of Cardiovascular R&D
Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.